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Abstract TGN38141 cycles between the trans-Golgi network 
(TGN) and plasma membrane, traversing three sorting compart- 
ments: the TGN, plasma membrane and early endosome. The 
targeting signals responsible for this complex itinerary reside in 
a short cytoplasmic domain of 33 amino acid residues. We show 
that phosphorylation of the cytoplasmic domain of TGN38 pre- 
vents binding of p62 - -  a cytoplasmic protein essential for ex- 
ocytic vesicle formation. Thus the cycle of TGN38/41 traffic, and 
by implication the pathway of exocytosis, could be controlled by 
phosphorylation of the TGN38 cytoplasmic domain. 
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I. Introduction 
TGN38/41 is a type I membrane glycoprotein predominantly 
located in the TGN [1]. Recent studies have shown that the 
cytoplasmic domain of TGN38/41 interacts with a cytosolic, 
autophosphorylating kinase called p62 in an essential step in 
exocytic vesicle formation [2,3]. A peptide corresponding to the 
last 12 amino acid residues o fTGN38 (CKASDYQRLNLKL)  
was able to prevent exocytic vesicle formation [2], implying that 
p62 interacts principally with this sequence. 
TGN38/41 becomes incorporated into the nascent exocytic 
vesicle and travels to the cell surface from which it is recycled 
back to the TGN [4-7]. Two targeting signals have been de- 
scribed for TGN38, a retention signal within the transmem- 
brane region [8], and a tyrosine tetrapeptide motif  (YQRL) 
located in the cytoplasmic domain [6,7,9]. The tyrosine and 
leucine residues of the YQRL moitif have been shown to be 
most important for internalisation of TGN38/41, suggesting 
that this signal is similar to that used for internalisation of 
recycling receptors [10,11]. Thus the signals for traffic of 
TGN38/41 in both directions are contained within the same 12 
residue sequence motif. 
We show here that p62 binds to the unphosphorylated form 
of the cytoplasmic domain of TGN38 and directly interacts 
with serine 24 (numbering from the start of the cytoplasmic 
domain), adjacent o the tyrosine internalisation motif. Fur- 
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thermore, phosphorylation of the cytoplasmic domain at serine 
15 or threonine 18 by PKC inhibits binding of p62. Thus the 
membrane traffic of TGN38/41 could be controlled by cycles 
of phosphorylation and dephosphorylation determining entry 
into the exocytic and endocytic pathways. 
2. Material and methods 
2.1. DNA cloning and protein preparation 
The cDNA encoding residues 5-33 of the cytoplasmic domain of 
TGN38 (amino acid sequence in single letter code: IIAFALE- 
GKRS~SKVT~SRRPKAS24DYQRLNLKL, numbers identify possible 
phosphorylation sites) was amplified by polymerase chain reaction 
using primers that inserted a BamHI site and two codons encoding 
glycine residues on the 5' side of the sequence inthe same reading frame 
as glutathione S-transferase (GST) and an EeoRI site downstream of 
the stop codon of TGN38. The amplified fragment was cloned into 
pGEX-2T cut with BamHI and EeoRI and expressed in JPA 101 cells. 
The fusion protein containing the $24A mutation was generated by the 
same strategy as the wild-type TGN38 tail fusion protein except hat 
a primer was used having the codon for serine changed to alanine. The 
GST fusion proteins were expressed and purified as described [12]. 
2.2. Phosphorylation 
Each 100/11 reaction contained 50 ¢tg of purified fusion protein and 
30/~Ci [32p]orthophosphate. The reaction was started with the addition 
of kinase to the reaction mixture for 5 min at 37°C. Reaction buffers 
for the purified kinases were as recommended by the supplier (PKA/ 
PKC: Boehringer Mannheim, CKII: Promega). For Fig. 1, lane 5, 
reaction buffer for PKC was used. The reaction was stopped by cooling 
and addition of glutathione-agarose beads in buffer A (20 mM HEPES, 
300 mM KCI, 50 mM EDTA and 20% (v/v) glycerol) containing 0.1 
mM pefablock. 5¢tg/ml aprotinin, 1mM benzamidine, 50 mM NaF and 
2 mM sodium vanadate. After 15 min binding at room temperature, the 
beads were washed 3 times in buffer A and then the fusion proteins 
eluted in PAGE sample buffer containing 4% SDS. Fifty percent of the 
reaction mix was separated on a 12% polyacrylamide g l which was 
then dried and analysed on a phosphorimage analyser (Berthold/Fuji). 
Images were quantitated asPSL and corrected for equal protein loading 
(in arbitrary units) from the scanned Coomassie Brilliant Blue stained 
gels. 
2.3. Cytosol fractionation 
A cytosol fraction was made from rat liver homogenate bysequential 
centrifugation at10,000 × g for 10 min and 100,000 x g for 60 min. The 
supernatant from the second centrifugation step was enriched in p62 
by ion exchange chromatography onDEAE-Sepharose eluted by step- 
wise (0.05 M) increases in NaCI concentration. A fraction eluted in 0.15 
M NaCI was found to contain the majority of the p62 by Western 
blotting. This material was concentrated and further purified by gel 
filtration on a 1.6 x 50 cm S-200 sephacryl column, p62 comprised 
approximately 5% of the enriched cytosol proteins as judged by 
Coomassie staining of SDS gels. 
2.4. Immune depletion 
Fifty microlitre samples of p62-enriched cytosol containing 110 ~tg 
of protein were incubated with 10/11 of pre-immune serum or anti-p62 
antiserum overnight at 4°C. The IgG was then removed from the 
cytosol fraction by incubation at 4°C for 2 h with 50/tl of a 1 : I slurry 
of protein A-Sepharose. Protein A-Sepharose was removed by centrif- 
ugation at 14,000 z g for 2 min. 
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2.5. p62 binding and cross linking 
GST-TGN38 fusion protein was phosphorylated with various ki- 
nases as described in Fig. 1 and then purified on glutathione-agarose 
beads. After 3 washes in buffer A, 1 ml of fresh rat liver cytosol 
(100,000 x g for 60 rain supernatant) was added for 2 h at room temper- 
ature. DTSSP in 5 mM sodium citrate buffer, pH 5, was added to a final 
concentration f 0.4 mM and incubated for a further 30 min at room 
temperature. The remaining cross-linker was quenched in50 mM Tris, 
pH 7.5, for 15 min on ice and the agarose beads then washed 3times 
in 6 M urea, 20 mM Tris, pH 7.5, containing protease and phosphatase 
inhibitors. The disulphide cross-link was cleaved in PAGE sample 
buffer containing 50 mM DTT and the proteins eparated on a 12% 
SDS gel. p62 was detected by Western blot and enhanced chemilumi- 
nescence detection (Amersham). 
3. Results and discussion 
We have studied the phosphorylation f the TGN38 cyto- 
plasmic domain expressed as a fusion protein with bacterial 
glutathione S-transferase (GST-TGN38). PKC phosphoryl- 
ated the GST TGN38 fusion protein more efficiently than 
PKA and CKII was without effect (Fig. 1). Rat liver cytosol, 
and cAMP-stimulated Golgi membranes ( ources of PKC and 
PKA in vivo) could also phosphorylate the fusion protein (data 
not shown). There was no phosphorylation f GST alone by 
any kinase tested, or of GST-TGN38 in the absence of added 
kinase (Fig. 1, lanes 4 and 5). It is perhaps not surprising that 
PKC was the most effective kinase as both serine residues (Sl5, 
$24) and the threonine residue (T 18) in the TGN38 cytoplasmic 
domain fall within consensus sequences for phosphorylation by 
this enzyme [13]. 
We next explored the possibility that p62, which has been 
shown to autophosphorylate [4],was able to phosphorylate he 
TGN38 cytoplasmic domain in the GST fusion protein. To our 
surprise we found that depleting a cytosol fraction with anti- 
p62 antiserum (Fig. 2, lanes 1 and 2) actually increased the 
amount of GST-TGN38 phosphorylation, suggesting that p62 
inhibited the phosphorylation reaction (Fig. 2, lanes 3 and 4). 
A possible explanation of this result is that p62 binds at, or 
close to, the site ofphosphorylation  the TGN38 cytoplasmic 
domain, thus masking it from kinases in the cytosol fraction. 
An extension of this line of reasoning is that phosphorylation 
of the cytoplasmic domain of TGN38 might prevent p62 bind- 
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Fig. 1. PKC and PKA can phosphorylate the cytoplasmic domain of 
TGN38 in vitro. Fifty micrograms of purified GST-TGN38 fusion 
protein were incubated with purified kinases at 37°C for 5 rain as 
follows: lane 1 = 0.05 mU (Casein) PKC; lane 2 = 0.4 units (Kemptide) 
PKA; lane 3 = 4 units of casein kinase II; lane 4 = GST alone; lane 
5 = no kinase added. 
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Fig. 2. p62 inhibits TGN38 phosphorylation in vitro. A rat liver cytosol 
fraction was treated with a pre-immune s rum (lanes 1 and 3) was or 
immunodepleted with anti-p62 serum (lanes 2 and 4) and tested for 
phosphorylation activity as described inFig. 1 (using a general phos- 
phorylation buffer: 2 mM MnCI2, 10 mM MgC12, 50 mM Yris, pH 7.5, 
1 mM CaCI2, 25 pM ATP and 30 ¢tCi [32P]orthophosphate). Lanes 1 
and 2 show a Western blot using anti-p62 antibody showing that deple- 
tion of p62 was effective (the lower band in lane 2 has the mobility of 
the antibody IgG heavy chain used for immunodepletion). Lanes 3 and 
4 show the [32p]orthophosphate incorporated into GST TGN38 fusion 
protein. 
ing. We tested this hypothesis by incubating phosphorylated 
and non-phosphorylated GST-TGN38 fusion protein with a 
fresh cytosol fraction and then analysing the amount of p62 
bound by affinity purification on agarose beads and then West- 
ern blotting. Fig. 3 shows that p62 binding was strongly inhib- 
ited by PKC phosphorylation f the GST-TGN38 fusion pro- 
tein (inhibition was 74 + 7%, mean + SEM). In the assay shown 
in Fig. 3A we cross-linked the proteins interacting with GST- 
TGN38 to allow more stringent washing conditions without 
loss of signal. Similar experiments without cross-linking and 
with 0.5 M salt washes gave a similar result, but with a lower 
signal-to-noise ratio. Interestingly, when PKA was used as ki- 
nase, binding of p62 was not disrupted, suggesting that PKA 
phosphorylates different residues compared with PKC. As ex- 
pected, CKII, which does not phosphorylate the fusion protein 
(Fig. 1), did not prevent p62 binding (Fig. 3A). 
The YQRL motif in TGN38 is preceded by a serine residue 
(SDYQRL) that has been implicated [9] as being important in 
determining the correct intracellular location of TGN38. We 
therefore made a fusion protein between GST and the TGN38 
cytoplasmic domain in which this serine was changed to alanine 
(GST-S24A), expecting that this mutant might bind p62 re- 
gardless of phosphorylation. Surprisingly, the $24A fusion pro- 
tein exhibited much reduced p62 binding compared to wild- 
type (Fig. 3B, compare lanes 1 and 2), suggesting that p62 
interacts directly with this residue. PKC was able to phospho- 
rylate the $24A mutant as well as the wild-type fusion protein 
(13396 + 1960 compared with 14572 + 1450 mean PSL/h/unit 
protein + S.E.M.), indicating that this serine is not a target for 
phosphorylation byPKC. Furthermore, PKC phosphorylation 
of $24A abolished the residual binding of p62 (Fig. 3B, lane 4) 
suggesting that either, or both, S15 or T18 are the principal 
targets for PKC phosphorylation a d control p62 binding. The 
$24A mutant was phosphorylated by PKA to a lower degree 
than wild-type GST-TGN38 (1208 + 188 compared with 
2062 _+ 305 mean PSL/h/unit protein + S.E.M.), but this phos- 
phorylation did not abolish the residual p62 binding that was 
apparent when using PKC (Fig. 3B, compare lanes 6 and 4). 
This confirmed the result in Fig. 3A. 
The ability of phosphorylation f the TGN38 cytoplasmic 
domain to prevent p62 binding suggests that phosphorylation 
might control TGN38/41 membrane traffic by flipping the 
structure of the TGN38 cytoplasmic tail between a p62 binding 
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Fig. 3. p62 binding to TGN38 is prevented by PKC phosphorylation 
and mutation of serine 24 of the TGN38 tail. (A) Effect of phosphoryl- 
ation on p62 binding. Lane 1--unphosphorylated control: lane 
2 = +PKC; lane 3 = +PKA; lane 4 = +casein kinase II; lane 5 = GST 
alone. (B) Effect of $24A mutation on p62 binding. Lanes l, 3 and 
5 = GST-TGN38 wild type; lanes 2, 4 and 6 = GST-S24A. Kinases 
added were: lanes 1 and 2, none; lanes 3 and 4, PKC; lanes 5 and 6, 
PKA. 
structure found in the TGN (unphosphorylated) and an AP-2 
binding structure found on the cell surface (phosphorylated). 
In support of this hypothesis it has been shown that the 
(unphosphorylated) TGN38 cytoplasmic tail peptide assumes 
a 'nascent helix' conformation i  solution [14] and not a tight 
turn as proposed for internalisation signals [10]. Thus p62 
might recognise the nascent helix form of the cytoplasmic do- 
main, and AP-2 the phosphorylated, presumably tight turn, 
conformation. It will be interesting to determine the 2D NMR 
structure of the phosphorylated TGN38 cytoplasmic domain 
peptide to see if this is the case. Further evidence comes from 
the observation [15] that treatment of NRK cells with okadaic 
acid leads to a 10-fold increase in surface TGN38/41. In the 
presence of okadaic acid, TGN38/41 would remain 
phosphorylated and become locked into the surface recycling 
pool. Another clue to the mechanism of TGN38/41 membrane 
traffic is the observation that mutation of R28 of the YQRL 
motif to D destroys internalisation of TGN38/41 beyond the 
early endosome [7]. On our hypothesis this could be due to 
inhibition of phosphatase r cognition of the cytoplasmic tail. 
A parallel situation has been described for the recruitment 
of AP-1 adaptors onto clathrin-coated vesicles at the TGN. 
Here, the casein kinase II-dependent phosphorylation f serine 
residues on the cation-independent MPR has been shown to be 
important for entry of this receptor into vesicles targeted to the 
late endosomes [16-19]. Thus transient phosphorylation may be 
a general mechanism for controlling the presentation of target- 
ing signals to the cytosolic sorting machinery, especially for 
proteins like TGN38/41 and the MPR which traverse more 
than one sorting compartment in the cell. 
Although exocytosis has been regarded as a constitutive 
process, implying a lack of control mechanisms, evidence is 
accumulating to indicate that both individual steps in the path- 
way, and the overall rate of release of secreted protein may be 
subject to control mechanisms involving kinases [20-22], 
heterotrimeric G proteins [23-25] and calcium [26]. Our data 
suggest hat increased phosphorylation retards the rate of ex- 
ocytic vesicle formation in as much as p62 recruitment onto 
TGN38/41 is required for this process. Phosphorylation has 
also been reported to inhibit the traffic of membrane proteins 
from ER to Golgi [20], between endosomes [27] and from recy- 
cling endosomes to the cell surface [28]. In contrast, exocytosis 
of secretory proteins can be stimulated by PKC [21], perhaps 
reflecting the different pathways of exocytosis for membrane 
and secretory components [29,30]. p62-dependent vesicle for- 
mation at the TGN may therefore be the mechanism of exocy- 
tosis for membrane proteins. 
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